Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Athira Pharma (ATHA) stocks in Canada

Learn how to easily invest in Athira Pharma stocks.

Athira Pharma is a biotechnology business based in the US. Athira Pharma stocks (ATHA.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $18.73 – a decrease of 9.5% over the previous week. Athira Pharma employs 20 staff and has a market cap (total outstanding stock value) of $412.7 million.

How to buy shares in Athira Pharma

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ATHA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Athira Pharma stock price (NASDAQ:ATHA)

Use our graph to track the performance of ATHA stocks over time.

Athira Pharma shares at a glance

Information last updated 2022-01-17.
Latest market close$10.00
52-week range$8.88 - $26.17
50-day moving average $13.48
200-day moving average $13.32
Wall St. target price$33.75
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.37

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
FREE TRADES
Wealthsimple Trade
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99 - $9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy Athira Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Athira Pharma price performance over time

Historical closes compared with the close of $10 from 2022-01-21

1 week (2022-01-14) -9.50%
1 month (2021-12-23) -23.14%
3 months (2021-10-22) -6.63%
6 months (2021-07-23) -1.86%
1 year (2021-01-22) -50.15%
2 years (2020-01-20) N/A
3 years (2019-01-20) N/A
5 years (2017-01-20) N/A

Athira Pharma financials

Gross profit TTM $0
Return on assets TTM -11.04%
Return on equity TTM -15.52%
Profit margin 0%
Book value $9.00
Market capitalisation $412.7 million

TTM: trailing 12 months

Athira Pharma share dividends

We're not expecting Athira Pharma to pay a dividend over the next 12 months.

Athira Pharma overview

Athira Pharma, Inc. , a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and stop neurodegradation. Its lead product candidate is ATH-1017, a blood brain barrier-penetrating, small hepatocyte growth factor/MET activator that is in LIFT-AD Phase II/III and ACT-AD Phase II clinical trials for the treatment of mild-to-moderate Alzheimer's disease, as well as in clinical development for Parkinson's disease. The company also develops product candidates, which are in preclinical stage, including ATH-1019/ATH-1020 for neuropsychiatric conditions; and ATH-1018 for peripheral nervous system disorders, such as neuropathy. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc.

Frequently asked questions


Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site